Summary financial information
Only figures from finalised accounts are published. The blanks below are filled in once confirmed.
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 41,280 | 44,650 | 48,700 |
| Cost of sales | 29,830 | 31,960 | 34,420 |
| Gross profit | 11,450 | 12,690 | 14,280 |
| Operating profit | 4,120 | 4,780 | 5,510 |
| Net profit | 3,140 | 3,590 | 4,260 |
| Total assets | 38,900 | 41,600 | 45,200 |
| Total liabilities | 18,700 | 19,400 | 20,100 |
| Total equity | 20,200 | 22,200 | 25,100 |
Revenue by segment
| Segment | Revenue | Share |
|---|---|---|
| Standard equipment | 19,480 | 40% |
| Engineered to order | 16,560 | 34% |
| Line integration | 7,790 | 16% |
| Service and parts | 4,870 | 10% |
Revenue by region
| Region | Revenue | Share |
|---|---|---|
| Korea | 35,530 | 73% |
| Asia | 6,330 | 13% |
| Europe | 3,410 | 7% |
| Middle East and Africa | 2,190 | 4.5% |
| Americas | 1,240 | 2.5% |
Using these figures
- The figures here are reference information, not investment advice or a solicitation.
- The finalised statements and the audit report are available on the disclosures page.
- Questions about the figures go to the IR contact.
IR contact: info@hanmiwoongpharma-kr.com